AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Passive immunotherapy appears to be an effective way to treat melanoma.
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- Passive immunotherapy should soon be a recognized way of effectively treating melanoma.
According to recent research published in the journal Bulletin du Cancer, "The protocols of tumor immunotherapy have been largely developed in the past 10 years, due to the identification of many tumor antigens recognized specifically by CD8 and CD4 T lymphocytes.
"Among the various immunotherapies currently tested, passive immunotherapy (i.e. injection of T lymphocytes generated and selected ex-vivo from blood or from the tumor), seems to be particularly promising. Indeed, 3 recent studies evidence the efficacy of such therapy in melanoma treatment. For the first time, a precise immunological follow-up was carried out, thus showing the correlation between the therapeutic benefit and the injection of tumor-antigen-specific T lymphocytes, and the survival and the preferential migration of these lymphocytes to the tumor sites," ...
- Research and Markets: Novel Tumor Vaccine Approaches - 'Passive' Immunotherapy...
- Press release article from: Business Wire May 11, 2004 700+ words
...immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way. There are, however, two cell therapies...
- Research and Markets: Cancer Vaccines Can Be Considered for Slowing Down...
- Press release article from: PR Newswire April 11, 2005 700+ words
DUBLIN, Ireland, April 11 /PRNewswire/ -- Research and Markets (httpwww.researchandmarkets.com/reports/c15485) has announced the addition of Cancer Vaccines Fantasy or Future? to their offering. (Logo: httpwww.newscom.com/cgi-bin/prnh/20040820/RESEARCH ) It has since several years continuously
- OMRIX Biopharmaceuticals Reports First Quarter 2006 Results.
- Press release article from: Business Wire May 10, 2006 700+ words
...develops and markets biosurgical and passive immunotherapy products, today reported financial...products in two areas: biosurgery and passive immunotherapy. The platforms supporting these...develops, manufactures, and markets passive immunotherapy products, focusing on hyperimmune...
- OMRIX Biopharmaceuticals Announces Third Quarter 2007 Financial...
- Press release article from: Business Wire November 5, 2007 700+ words
...develops and markets biosurgical and passive immunotherapy products, today announced financial...biosurgical products and non-biodefense passive immunotherapy products continued to grow and...two businesses, biosurgery and passive immunotherapy. Product sales from biosurgery...
- In- Depth Research on Omrix Biopharmaceuticals, Inc.
- Press release article from: M2 Presswire June 29, 2007 700+ words
...protein-based biosurgery and passive immunotherapy products. OMRIX' biosurgery product...medical need. The Company's passive immunotherapy product line includes antibody...protein-based biosurgery and passive immunotherapy products, announced Thursday 2007...
- OMRIX RECEIVES APPROVAL FOR LIQUID FIBRIN SEALANT, EVICEL.
- News wire article from: AsiaPulse News May 15, 2007 700+ words
...protein-based biosurgery and passive immunotherapy products, announced that on May...protein-based biosurgery and passive immunotherapy products. OMRIX' biosurgery product...medical need. The Company's passive immunotherapy product line includes antibody...
- OMRIX Biopharmaceuticals to Webcast Presentation at Acumen BioFin 4th Annual...
- Press release article from: Business Wire April 30, 2007 700+ words
...protein-based biosurgery and passive immunotherapy products, announced today that...protein-based biosurgery and passive immunotherapy products. OMRIX' biosurgery product...medical need. The Company's passive immunotherapy product line includes antibody...
- OMRIX Biopharmaceuticals Announces First Quarter 2007 Financial Results Date...
- Press release article from: Business Wire April 17, 2007 700+ words
...protein-based biosurgery and passive immunotherapy products, will announce financial...protein-based biosurgery and passive immunotherapy products. OMRIX' biosurgery product...medical need. The Company's passive immunotherapy product line includes antibody...